JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT

Attached files

file	filename
8-K - 8-K - JOHNSON & JOHNSON	a2013q28kcover.htm
EX-99.15 - EXHIBIT - JOHNSON & JOHNSON	a2013q28kexhibit9915.htm

Exhibit 99.2O



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SECOND QUARTER

	2013				2012				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	17,877		100.0	$	16,475		100.0	8.5
Cost of products sold	5,489			30.7	5,143			31.2	6.7
Selling, marketing and administrative expenses	5,376			30.1	4,965			30.1	8.3
Research and development expense	1,946			10.9	1,766			10.7	10.2
In-process research and development	—			—	429			2.6
Interest (income) expense, net	101			0.6	129			0.8
Other (income) expense, net	172			0.9	2,008			12.2
Earnings before provision for taxes on income	4,793			26.8	2,035			12.4	135.5
Provision for taxes on income	960			5.4	627			3.9	53.1
Net earnings	$	3,833		21.4	$	1,408		8.5	172.2

Net earnings per share (Diluted)	$	1.33			$	0.50			166.0

Average shares outstanding (Diluted)	2,893.0				2,798.2

Effective tax rate	20.0		%		30.8		%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$	5,359		30.0	$	4,646		28.2	15.3
Net earnings	$	4,289		24.0	$	3,644		22.1	17.7
Net earnings per share (Diluted)	$	1.48			$	1.30			13.8
Effective tax rate	20.0		%		21.6		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)	SIX MONTHS

	2013				2012				Percent
				Percent				Percent	Increase
	Amount			to Sales	Amount			to Sales	(Decrease)
Sales to customers	$	35,382		100.0	$	32,614		100.0	8.5
Cost of products sold	11,043			31.2	10,058			30.8	9.8
Selling, marketing and administrative expenses	10,599			30.0	9,980			30.6	6.2
Research and development expense	3,730			10.5	3,411			10.5	9.4
In-process research and development	64			0.2	429			1.3
Interest (income) expense, net	205			0.6	259			0.8
Other (income) expense, net	687			1.9	1,397			4.3
Earnings before provision for taxes on income	9,054			25.6	7,080			21.7	27.9
Provision for taxes on income	1,724			4.9	1,762			5.4	(2.2	)
Net earnings	$	7,330		20.7	$	5,318		16.3	37.8

Net earnings per share (Diluted)	$	2.55			$	1.91			33.5

Average shares outstanding (Diluted)	2,878.8				2,792.4

Effective tax rate	19.0		%		24.9		%

Adjusted earnings before provision for taxes and net earnings ^{(1) (A)}
Earnings before provision for taxes on income	$	10,429		29.5	$	9,574		29.4	8.9
Net earnings	$	8,396		23.7	$	7,448		22.8	12.7
Net earnings per share (Diluted)	$	2.92			$	2.67			9.4
Effective tax rate	19.5		%		22.2		%

⁽¹⁾ See Reconciliation of Non-GAAP Financial Measures.

^(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, these measures may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as significant costs associated with acquisitions, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, restructuring, litigation, and changes in applicable laws and regulations (including significant accounting or tax matters) and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
				Percent Change
	2013		2012	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$	1,326	1,313	1.0	%	1.0	—
International	2,332		2,306	1.1		2.0	(0.9	)
	3,658		3,619	1.1		1.7	(0.6	)

Pharmaceutical
U.S.	3,377		3,094	9.1		9.1	—
International	3,648		3,197	14.1		16.5	(2.4	)
	7,025		6,291	11.7		12.9	(1.2	)

Med Devices & Diagnostics
U.S.	3,243		2,953	9.8		9.8	—
International	3,951		3,612	9.4		13.7	(4.3	)
	7,194		6,565	9.6		12.0	(2.4	)

U.S.	7,946		7,360	8.0		8.0	—
International	9,931		9,115	9.0		11.8	(2.8	)
Worldwide	$	17,877	16,475	8.5	%	10.0	(1.5	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
				Percent Change
	2013		2012	Total		Operations	Currency
Sales to customers by
segment of business

Consumer
U.S.	$	2,674	2,629	1.7	%	1.7	—
International	4,659		4,585	1.6		2.9	(1.3	)
	7,333		7,214	1.6		2.4	(0.8	)

Pharmaceutical
U.S.	6,848		6,120	11.9		11.9	—
International	6,945		6,304	10.2		12.4	(2.2	)
	13,793		12,424	11.0		12.1	(1.1	)

Med Devices & Diagnostics
U.S.	6,449		5,830	10.6		10.6	—
International	7,807		7,146	9.2		12.9	(3.7	)
	14,256		12,976	9.9		12.0	(2.1	)

U.S.	15,971		14,579	9.5		9.5	—
International	19,411		18,035	7.6		10.2	(2.6	)
Worldwide	$	35,382	32,614	8.5	%	9.9	(1.4	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SECOND QUARTER
					Percent Change
	2013		2012		Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$	7,946	7,360		8.0	%	8.0	—

Europe	4,672		4,165		12.2		11.4	0.8
Western Hemisphere excluding U.S.	1,905		1,728		10.2		14.0	(3.8	)
Asia-Pacific, Africa	3,354		3,222		4.1		11.0	(6.9	)
International	9,931		9,115		9.0		11.8	(2.8	)

Worldwide	$	17,877	$	16,475	8.5	%	10.0	(1.5	)



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)	SIX MONTHS
					Percent Change
	2013		2012		Total		Operations	Currency
Sales to customers by
geographic area

U.S.	$	15,971	14,579		9.5	%	9.5	—

Europe	9,153		8,359		9.5		8.8	0.7
Western Hemisphere excluding U.S.	3,688		3,442		7.1		11.5	(4.4	)
Asia-Pacific, Africa	6,570		6,234		5.4		11.4	(6.0	)
International	19,411		18,035		7.6		10.2	(2.6	)

Worldwide	$	35,382	$	32,614	8.5	%	9.9	(1.4	)



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Second Quarter			% Incr. /
(Dollars in Millions Except Per Share Data)	2013		2012	(Decr.)

Earnings before provision for taxes on income - as reported	$	4,793	2,035	135.5	%

Intangible asset write-downs	—		939

Litigation expenses	375		669

Synthes integration/transaction costs and currency related	122		574

In-process research and development	—		429

DePuy ASR™ Hip program	69		—

Other	—		—

Earnings before provision for taxes on income - as adjusted	$	5,359	4,646	15.3	%

Net Earnings - as reported	$	3,833	1,408	172.2	%

Intangible asset write-downs	—		717

Litigation expenses	308		611

Synthes integration/transaction costs and currency related	87		564

In-process research and development	—		344

DePuy ASR™ Hip program	61		—

Other	—		—

Net Earnings - as adjusted	$	4,289	3,644	17.7	%

Diluted Net Earnings per share - as reported	$	1.33	0.50	166.0	%

Intangible asset write-downs	—		0.26

Litigation expenses	0.10		0.22

Synthes integration/transaction costs and currency related	0.03		0.20

In-process research and development	—		0.12

DePuy ASR™ Hip program	0.02		—

Other	—		—

Diluted Net Earnings per share - as adjusted	$	1.48	1.30	13.8	%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

	Six Months YTD					% Incr. /
(Dollars in Millions Except Per Share Data)	2013			2012		(Decr.)

Earnings before provision for taxes on income - as reported	$	9,054		$	7,080	27.9	%

Intangible asset write-downs	—			939

Litigation expenses	904			669

Synthes integration/transaction costs and currency related	380			457

In-process research and development	64			429

DePuy ASR™ Hip program	82			—

Other	(55		)	—

Earnings before provision for taxes on income - as adjusted	$	10,429		9,574		8.9	%

Net Earnings - as reported	$	7,330		5,318		37.8	%

Intangible asset write-downs	—			717

Litigation expenses	699			611

Synthes integration/transaction costs and currency related	270			458

In-process research and development	42			344

DePuy ASR™ Hip program	91			—

Other	(36		)	—

Net Earnings - as adjusted	$	8,396		7,448		12.7	%

Diluted Net Earnings per share - as reported	$	2.55		1.91		33.5	%

Intangible asset write-downs	—			0.26

Litigation expenses	0.24			0.22

Synthes integration/transaction costs and currency related	0.09			0.16

In-process research and development	0.02			0.12

DePuy ASR™ Hip program	0.03			—

Other	(0.01		)	—

Diluted Net Earnings per share - as adjusted	$	2.92		2.67		9.4	%

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT^{(2) (4)}

BABY CARE
US	$	106	106	0.0	%	0.0	%	—	%
Intl		480	472	1.7		3.8		(2.1	)
WW		586	578	1.4		3.1		(1.7	)

ORAL CARE
US		149	159	(6.3)		(6.3)		—
Intl		257	249	3.2		4.3		(1.1	)
WW		406	408	(0.5	)	0.2		(0.7	)

OTC⁽³⁾
US		290	247	17.4		17.4		—
Intl		641	636	0.8		0.9		(0.1	)
WW		931	883	5.4		5.4		0.0

SKIN CARE
US		463	471	(1.7	)	(1.7	)	—
Intl		445	442	0.7		1.0		(0.3	)
WW		908	913	(0.5	)	(0.4	)	(0.1	)

WOMEN'S HEALTH
US		84	80	5.0		5.0		—
Intl		327	322	1.6		3.4		(1.8	)
WW		411	402	2.2		3.6		(1.4	)

WOUND CARE/OTHER⁽³⁾
US		234	250	(6.4	)	(6.4	)	—
Intl		182	185	(1.6	)	(1.4	)	(0.2	)
WW		416	435	(4.4	)	(4.3	)	(0.1	)

TOTAL CONSUMER
US		1,326	1,313	1.0		1.0		—
Intl		2,332	2,306	1.1		2.0		(0.9	)
WW	$	3,658	3,619	1.1	%	1.7	%	(0.6	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	1,578	1,471	7.3	%	7.3	%	—	%
Intl		663	448	48.0		51.5		(3.5	)
WW		2,241	1,919	16.8		17.6		(0.8	)
REMICADE
US		926	890	4.0		4.0		—
US Exports⁽⁵⁾		332	366	(9.3	)	(9.3	)	—
Intl		414	267	55.1		58.2		(3.1	)
WW		1,672	1,523	9.8		10.3		(0.5	)
SIMPONI
US		87	63	38.1		38.1		—
Intl		88	62	41.9		48.3		(6.4	)
WW		175	125	40.0		43.2		(3.2	)
STELARA
US		233	152	53.3		53.3		—
Intl		138	96	43.8		45.4		(1.6	)
WW		371	248	49.6		50.2		(0.6	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		23	23	0.0		1.1		(1.1	)
WW		23	23	0.0		1.1		(1.1	)

INFECTIOUS DISEASES
US		259	237	9.3		9.3		—
Intl		711	551	29.0		30.2		(1.2	)
WW		970	788	23.1		23.9		(0.8	)
INCIVO
US		—	—	—		—		—
Intl		172	102	68.6		71.8		(3.2	)
WW		172	102	68.6		71.8		(3.2	)
INTELENCE
US		44	42	4.8		4.8		—
Intl		59	49	20.4		21.0		(0.6	)
WW		103	91	13.2		13.5		(0.3	)
PREZISTA
US		196	166	18.1		18.1		—
Intl		239	207	15.5		16.0		(0.5	)
WW		435	373	16.6		16.9		(0.3	)
OTHER INFECTIOUS DISEASES
US		19	29	(34.5	)	(34.5	)	—
Intl		241	193	24.9		25.8		(0.9	)
WW		260	222	17.1		17.9		(0.8	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	626	658	(4.9	)%	(4.9	)%	—	%
Intl		1,054	1,056	(0.2	)	3.8		(4.0	)
WW		1,680	1,714	(2.0	)	0.4		(2.4	)
CONCERTA/METHYLPHENIDATE
US		85	146	(41.8	)	(41.8	)	—
Intl		130	122	6.6		8.9		(2.3	)
WW		215	268	(19.8	)	(18.7	)	(1.1	)
INVEGA
US		76	76	0.0		0.0		—
Intl		74	66	12.1		18.3		(6.2	)
WW		150	142	5.6		8.4		(2.8	)
INVEGA SUSTENNA/XEPLION
US		158	120	31.7		31.7		—
Intl		132	75	76.0		75.0		1.0
WW		290	195	48.7		48.3		0.4
RISPERDAL CONSTA
US		107	110	(2.7	)	(2.7	)	—
Intl		229	245	(6.5	)	(3.7	)	(2.8	)
WW		336	355	(5.4	)	(3.5	)	(1.9	)
OTHER NEUROSCIENCE
US		200	206	(2.9	)	(2.9	)	—
Intl		489	548	(10.8	)	(5.5	)	(5.3	)
WW		689	754	(8.6	)	(4.8	)	(3.8	)

ONCOLOGY
US		206	119	73.1		73.1		—
Intl		679	467	45.4		48.1		(2.7	)
WW		885	586	51.0		53.2		(2.2	)
VELCADE
US		—	—	—		—		—
Intl		379	318	19.2		22.7		(3.5	)
WW		379	318	19.2		22.7		(3.5	)
ZYTIGA
US		174	113	54.0		54.0		—
Intl		221	119	85.7		85.2		0.5
WW		395	232	70.3		70.0		0.3
OTHER ONCOLOGY
US		32	6	*		*		—
Intl		79	30	*		*		(7.4	)
WW		111	36	*		*		(6.1	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	708	609	16.3	%	16.3	%	—	%
Intl		541	675	(19.9	)	(19.9	)	0.0
WW		1,249	1,284	(2.7	)	(2.7	)	0.0
ACIPHEX/PARIET
US		97	104	(6.7	)	(6.7	)	—
Intl		59	128	(53.9	)	(54.0	)	0.1
WW		156	232	(32.8	)	(32.8	)	0.0
PROCRIT/EPREX
US		190	232	(18.1	)	(18.1	)	—
Intl		145	169	(14.2	)	(14.6	)	0.4
WW		335	401	(16.5	)	(16.7	)	0.2
XARELTO
US		189	49	*		*		—
Intl		—	—	—		—		—
WW		189	49	*		*		—
OTHER
US		232	224	3.6		3.6		—
Intl		337	378	(10.8	)	(10.5	)	(0.3	)
WW		569	602	(5.5	)	(5.3	)	(0.2	)

TOTAL PHARMACEUTICAL
US		3,377	3,094	9.1		9.1		—
Intl		3,648	3,197	14.1		16.5		(2.4	)
WW	$	7,025	6,291	11.7	%	12.9	%	(1.2	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SECOND QUARTER
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾

CARDIOVASCULAR CARE
US	$	204	195	4.6	%	4.6	%	—	%
Intl		325	309	5.2		9.6		(4.4	)
WW		529	504	5.0		7.7		(2.7	)

DIABETES CARE
US		259	337	(23.1	)	(23.1	)	—
Intl		330	336	(1.8	)	(0.5	)	(1.3	)
WW		589	673	(12.5	)	(11.8	)	(0.7	)

DIAGNOSTICS
US		241	258	(6.6	)	(6.6	)	—
Intl		242	256	(5.5	)	(1.5	)	(4.0	)
WW		483	514	(6.0	)	(4.0	)	(2.0	)

INFECTION PREVENTION/OTHER
US		95	99	(4.0	)	(4.0	)	—
Intl		139	131	6.1		12.3		(6.2	)
WW		234	230	1.7		5.2		(3.5	)

ORTHOPAEDICS
US		1,274	873	45.9		45.9		—
Intl		1,111	755	47.2		52.4		(5.2	)
WW		2,385	1,628	46.5		48.9		(2.4	)

SPECIALTY SURGERY
US		331	336	(1.5	)	(1.5	)	—
Intl		325	310	4.8		7.5		(2.7	)
WW		656	646	1.5		2.8		(1.3	)

SURGICAL CARE
US		577	602	(4.2	)	(4.2	)	—
Intl		1,011	1,038	(2.6	)	0.6		(3.2	)
WW		1,588	1,640	(3.2	)	(1.2	)	(2.0	)

VISION CARE
US		262	253	3.6		3.6		—
Intl		468	477	(1.9	)	6.4		(8.3	)
WW		730	730	0.0		5.4		(5.4	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		3,243	2,953	9.8		9.8		—
Intl		3,951	3,612	9.4		13.7		(4.3	)
WW	$	7,194	6,565	9.6	%	12.0	%	(2.4	)%
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
CONSUMER SEGMENT^{(2) (4)}

BABY CARE
US	$	209	205	2.0	%	2.0	%	—	%
Intl		941	913	3.1		5.7		(2.6	)
WW		1,150	1,118	2.9		5.0		(2.1	)

ORAL CARE
US		307	314	(2.2	)	(2.2	)	—
Intl		502	481	4.4		5.8		(1.4	)
WW		809	795	1.8		2.6		(0.8	)

OTC ⁽³⁾
US		644	538	19.7		19.7		—
Intl		1,330	1,296	2.6		3.0		(0.4	)
WW		1,974	1,834	7.6		7.9		(0.3	)

SKIN CARE
US		916	924	(0.9	)	(0.9	)	—
Intl		894	896	(0.2	)	0.3		(0.5	)
WW		1,810	1,820	(0.5	)	(0.3	)	(0.2	)

WOMEN'S HEALTH
US		165	173	(4.6	)	(4.6	)	—
Intl		647	638	1.4		4.1		(2.7	)
WW		812	811	0.1		2.2		(2.1	)

WOUND CARE/OTHER ⁽³⁾
US		433	475	(8.8	)	(8.8	)	—
Intl		345	361	(4.4	)	(4.0	)	(0.4	)
WW		778	836	(6.9	)	(6.7	)	(0.2	)

TOTAL CONSUMER
US		2,674	2,629	1.7		1.7		—
Intl		4,659	4,585	1.6		2.9		(1.3	)
WW	$	7,333	7,214	1.6	%	2.4	%	(0.8	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2013	2012	Reported		Operational⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4)}

IMMUNOLOGY
US	$	3,217	2,924	10.0	%	10.0	%	—	%
Intl		1,228	890	38.0		40.9		(2.9	)
WW		4,445	3,814	16.5		17.2		(0.7	)
REMICADE
US		1,896	1,772	7.0		7.0		—
US Exports⁽⁵⁾		681	744	(8.5	)	(8.5	)	—
Intl		695	528	31.6		34.0		(2.4	)
WW		3,272	3,044	7.5		7.9		(0.4	)
SIMPONI
US		181	127	42.5		42.5		—
Intl		231	114	*		*		(4.5	)
WW		412	241	71.0		73.5		(2.5	)
STELARA
US		459	281	63.3		63.3		—
Intl		258	188	37.2		38.4		(1.2	)
WW		717	469	52.9		53.4		(0.5	)
OTHER IMMUNOLOGY
US		—	—	—		—		—
Intl		44	60	(26.7	)	(26.1	)	(0.6	)
WW		44	60	(26.7	)	(26.1	)	(0.6	)

INFECTIOUS DISEASES
US		497	479	3.8		3.8		—
Intl		1,288	1,064	21.1		22.2		(1.1	)
WW		1,785	1,543	15.7		16.5		(0.8	)
INCIVO
US		—	—	—		—		—
Intl		334	234	42.7		45.4		(2.7	)
WW		334	234	42.7		45.4		(2.7	)
INTELENCE
US		91	85	7.1		7.1		—
Intl		101	86	17.4		18.0		(0.6	)
WW		192	171	12.3		12.6		(0.3	)
PREZISTA
US		363	326	11.3		11.3		—
Intl		439	371	18.3		18.7		(0.4	)
WW		802	697	15.1		15.3		(0.2	)
OTHER INFECTIOUS DISEASES
US		43	68	(36.8	)	(36.8	)	—
Intl		414	373	11.0		11.9		(0.9	)
WW		457	441	3.6		4.3		(0.7	)

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

NEUROSCIENCE
US	$	1,372	1,332	3.0	%	3.0	%	—	%
Intl		2,052	2,029	1.1		4.6		(3.5	)
WW		3,424	3,361	1.9		4.0		(2.1	)
CONCERTA/METHYLPHENIDATE
US		224	343	(34.7	)	(34.7	)	—
Intl		247	233	6.0		7.9		(1.9	)
WW		471	576	(18.2	)	(17.4	)	(0.8	)
INVEGA
US		147	145	1.4		1.4		—
Intl		135	118	14.4		19.9		(5.5	)
WW		282	263	7.2		9.7		(2.5	)
INVEGA SUSTENNA/XEPLION
US		322	220	46.4		46.4		—
Intl		252	136	85.3		84.4		0.9
WW		574	356	61.2		60.9		0.3
RISPERDAL CONSTA
US		213	223	(4.5	)	(4.5	)	—
Intl		458	493	(7.1	)	(4.9	)	(2.2	)
WW		671	716	(6.3	)	(4.8	)	(1.5	)
OTHER NEUROSCIENCE
US		466	401	16.2		16.2		—
Intl		960	1,049	(8.5	)	(3.7	)	(4.8	)
WW		1,426	1,450	(1.7	)	1.8		(3.5	)

ONCOLOGY
US		405	226	79.2		79.2		—
Intl		1,274	956	33.3		35.8		(2.5	)
WW		1,679	1,182	42.0		44.0		(2.0	)
VELCADE
US		—	—	—		—		—
Intl		732	671	9.1		12.1		(3.0	)
WW		732	671	9.1		12.1		(3.0	)
ZYTIGA
US		335	213	57.3		57.3		—
Intl		404	219	84.5		84.4		0.1
WW		739	432	71.1		71.1		0.0
OTHER ONCOLOGY
US		70	13	*		*		—
Intl		138	66	*		*		(6.0	)
WW		208	79	*		*		(5.0	)
See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
PHARMACEUTICAL SEGMENT^{(2) (4) (Continued)}

TOTAL OTHER
US	$	1,357	1,159	17.1	%	17.1	%	—	%
Intl		1,103	1,365	(19.2	)	(18.6	)	(0.6	)
WW		2,460	2,524	(2.5	)	(2.2	)	(0.3	)
ACIPHEX/PARIET
US		200	200	0.0		0.0		—
Intl		108	254	(57.5	)	(57.3	)	(0.2	)
WW		308	454	(32.2	)	(32.1	)	(0.1	)
PROCRIT/EPREX
US		423	436	(3.0	)	(3.0	)	—
Intl		290	341	(15.0	)	(15.3	)	0.3
WW		713	777	(8.2	)	(8.3	)	0.1
XARELTO
US		347	76	*		*		—
Intl		—	—	—		—		—
WW		347	76	*		*		—
OTHER
US		387	447	(13.4	)	(13.4	)	—
Intl		705	770	(8.4	)	(7.4	)	(1.0	)
WW		1,092	1,217	(10.3	)	(9.7	)	(0.6	)

TOTAL PHARMACEUTICAL
US		6,848	6,120	11.9		11.9		—
Intl		6,945	6,304	10.2		12.4		(2.2	)
WW	$	13,793	12,424	11.0	%	12.1	%	(1.1	)%

See footnotes at end of schedule



Johnson & Johnson
Segment Sales
(Dollars in Millions)
		SIX MONTHS
				% Change
		2013	2012	Reported		Operational ⁽¹⁾		Currency
MEDICAL DEVICES AND DIAGNOSTICS ⁽²⁾

CARDIOVASCULAR CARE
US	$	402	371	8.4	%	8.4	%	—	%
Intl		640	615	4.1		8.0		(3.9	)
WW		1,042	986	5.7		8.1		(2.4	)
DIABETES CARE
US		542	689	(21.3	)	(21.3	)	—
Intl		647	654	(1.1	)	0.2		(1.3	)
WW		1,189	1,343	(11.5	)	(10.9	)	(0.6	)
DIAGNOSTICS
US		489	511	(4.3	)	(4.3	)	—
Intl		471	515	(8.5	)	(4.7	)	(3.8	)
WW		960	1,026	(6.4	)	(4.5	)	(1.9	)
INFECTION PREVENTION/OTHER
US		180	215	(16.3	)	(16.3	)	—
Intl		266	259	2.7		8.2		(5.5	)
WW		446	474	(5.9	)	(2.9	)	(3.0	)
ORTHOPAEDICS
US		2,535	1,656	53.1		53.1		—
Intl		2,235	1,465	52.6		56.3		(3.7	)
WW		4,770	3,121	52.8		54.5		(1.7	)
SPECIALTY SURGERY
US		650	663	(2.0	)	(2.0	)	—
Intl		633	611	3.6		6.2		(2.6	)
WW		1,283	1,274	0.7		1.9		(1.2	)
SURGICAL CARE
US		1,108	1,195	(7.3	)	(7.3	)	—
Intl		1,988	2,070	(4.0	)	(1.0	)	(3.0	)
WW		3,096	3,265	(5.2	)	(3.3	)	(1.9	)
VISION CARE
US		543	530	2.5		2.5		—
Intl		927	957	(3.1	)	4.1		(7.2	)
WW		1,470	1,487	(1.1	)	3.5		(4.6	)

TOTAL MEDICAL DEVICES AND DIAGNOSTICS
US		6,449	5,830	10.6		10.6		—
Intl		7,807	7,146	9.2		12.9		(3.7	)
WW	$	14,256	12,976	9.9	%	12.0	%	(2.1	)%
*Percentage greater than 100%
⁽¹⁾Operational growth excludes the effect of currency
⁽²⁾ Select areas (unaudited)
⁽³⁾ Nutritionals now reflected in Wound Care/Other, previously reported in OTC/Nutritionals
⁽⁴⁾Prior year amounts have been reclassified to conform to current year product disclosure
⁽⁵⁾Reported as U.S. sales



Johnson & Johnson
Segment Sales
(Dollars in Millions)

Supplemental Sales Information
		2012					2013
		Q1	Q2	Q3	Q4	FY	Q1
OTC
US	$	291	247	263	273	1,074	354
Intl		660	636	653	743	2,692	689
WW		951	883	916	1,016	3,766	1,043

WOUND CARE/OTHER
US		225	250	214	195	884	199
Intl		176	185	163	152	676	163
WW	$	401	435	377	347	1,560	362

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

Also read

JOHNSON & JOHNSON - FORM 8-K - EX-99.2O - EXHIBIT - July 16, 2013

Attached files

Stock widget

Investing forum

JOHNSON & JOHNSON Reports

Also read